Advertisement
Advertisement
OncoCyte Corporation (OCX)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.40000.0000 (0.00%)
At close: 4:00PM EDT
Advertisement
Currency in USD
Valuation Measures
Yahoo Finance Plus required to access annual data
Annual
Quarterly
Yahoo Finance Plus required to access monthly dataMonthly
Subscribe to Yahoo Finance Plus Essential to download historical data| Â | As of Date: 10/27/2021Current |
|---|---|
| Market Cap (intraday) 5 | N/A |
| Enterprise Value 3 | N/A |
| Trailing P/E | N/A |
| Forward P/E 1 | N/A |
| PEG Ratio (5 yr expected) 1 | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue 3 | N/A |
| Enterprise Value/EBITDA 7 | N/A |
Trading Information
Stock Price History
| Beta (5Y Monthly) | 1.91 |
| 52-Week Change 3 | N/A |
| S&P500 52-Week Change 3 | N/A |
| 52 Week High 3 | 6.5700 |
| 52 Week Low 3 | 1.4100 |
| 50-Day Moving Average 3 | 3.6078 |
| 200-Day Moving Average 3 | 4.5372 |
Share Statistics
| Avg Vol (3 month) 3 | 604.8k |
| Avg Vol (10 day) 3 | 300.74k |
| Shares Outstanding 5 | 89.87M |
| Implied Shares Outstanding 6 | N/A |
| Float 8 | 53.01M |
| % Held by Insiders 1 | 10.33% |
| % Held by Institutions 1 | 63.54% |
| Shares Short (Sep 29, 2021) 4 | 2.3M |
| Short Ratio (Sep 29, 2021) 4 | 4.6 |
| Short % of Float (Sep 29, 2021) 4 | 3.76% |
| Short % of Shares Outstanding (Sep 29, 2021) 4 | 2.48% |
| Shares Short (prior month Aug 30, 2021) 4 | 2.92M |
Dividends & Splits
| Forward Annual Dividend Rate 4 | N/A |
| Forward Annual Dividend Yield 4 | N/A |
| Trailing Annual Dividend Rate 3 | N/A |
| Trailing Annual Dividend Yield 3 | N/A |
| 5 Year Average Dividend Yield 4 | N/A |
| Payout Ratio 4 | 0.00% |
| Dividend Date 3 | N/A |
| Ex-Dividend Date 4 | N/A |
| Last Split Factor 2 | N/A |
| Last Split Date 3 | N/A |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | Dec 30, 2020 |
| Most Recent Quarter (mrq) | Jun 29, 2021 |
Profitability
| Profit Margin | 0.00% |
| Operating Margin (ttm) | -826.26% |
Management Effectiveness
| Return on Assets (ttm) | -18.06% |
| Return on Equity (ttm) | -38.67% |
Income Statement
| Revenue (ttm) | 4.21M |
| Revenue Per Share (ttm) | 0.05 |
| Quarterly Revenue Growth (yoy) | 1,319.60% |
| Gross Profit (ttm) | -639k |
| EBITDA | -32.86M |
| Net Income Avi to Common (ttm) | -27.5M |
| Diluted EPS (ttm) | -0.3700 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 47.53M |
| Total Cash Per Share (mrq) | 0.52 |
| Total Debt (mrq) | 6.67M |
| Total Debt/Equity (mrq) | 6.50 |
| Current Ratio (mrq) | 2.53 |
| Book Value Per Share (mrq) | 1.20 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -30.07M |
| Levered Free Cash Flow (ttm) | -3.1M |
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
